Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.

By J. Berndt, N. Klöting, S. Kralisch, P. Kovacs, M. Fasshauer, M. Schön, M. Stumvoll, M. Blüher. Diabetes, 2005

795 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties1 (2007, background): “Moreover, visfatin-induced IL-6 expression might be involved in the pathogenesis of insulin resistance associated with visceral obesity (56).”
Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease (2014, background): “However, serum visfatin levels and expression of visfatin in adipose tissue are not correlated with glucose metabolism or insulin resistance [137,142].”
The metabolic syndrome. (2008, background): “associated with BMI and percent body fat (243).”
Omentin Plasma Levels and Gene Expression Are Decreased in Obesity (2007, result): “In contrast with omentin and adiponectin (38), which show obesity-dependent decreases in gene expression, visfatin was previously shown to have obesity-dependent increases in visceral fat gene expression (37,39).”
Adipokines: the missing link between insulin resistance and obesity. (2008, background): “[82] Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al.”
Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. (2007, background): “372 Cell Metabolism 6, 363–375, November 2007 a2007 Elsevi are associated with higher body mass index and percent body fat (Berndt et al., 2005), type 2 diabetes (Chen et al.”